At least that's what the latest presser out of Whitehouse Station proclaims:
. . . .Richard T. Clark, chairman and chief executive officer, Merck. "We look forward to furthering our discussions with Sinopharm to establish a joint venture to significantly increase the number of people in China who have access to important vaccines."
Merck and Sinopharm have maintained a good relationship for many years, Sinopharm said. Both Merck and Sinopharm expect the importance of public health will be elevated and the development of the pharmaceutical industry in China will be promoted through this strategic cooperation. . . .
It is certain that China has required some local manufacturing -- for inside China deliveries, and presumably, at very low price points -- in order for Merck to secure access to her vast market-potentials. What is unlcear is whether any of these HPV vaccine-stocks (or other future vaccine-stocks) will be made available for export. Here's one recent backgrounder.
No comments:
Post a Comment